Hypoparathyroidism is a rare condition characterized by the diminished function or absence of parathyroid hormone (PTH). PTH ...

Expert Rev Endocrinol Metab. 2012;7(3):255-257. The future of hormone replacement therapy in hypoparathyroidism can be viewed with optimism, even if we are left with several unanswered questions ...

There’s no cure for hypoparathyroidism, but treatment options like calcium supplements, diuretics, and parathyroid hormone therapy can help regulate your calcium and phosphate levels.

UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic hypoparathyroidism. The Calypso trial (NCT05778071) of eneboparatide, an ...

UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic hypoparathyroidism. The Calypso trial (NCT05778071) of eneboparatide ...

Topline data were announced from a phase 3 trial evaluating eneboparatide in adults with chronic hypoparathyroidism.

AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for small cell lung cancer treatment.

Considering taking supplements to treat hypoparathyroidism? Below is a list of common natural remedies used to treat or reduce the symptoms of hypoparathyroidism. Follow the links to read common ...

After turning it down a year ago, the FDA has cleared once-daily injectable Yorvipath for hypoparathyroidism from Ascendis Pharma. Yorvipath (palopegteriparatide) – previously known as TransCon ...

Important research news last week included UK pharma major AstraZeneca releasing encouraging results from the CALYPSO Phase ...

High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical ...